866-997-4948(US-Canada Toll Free)

Metastatic Colorectal Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Jul 2013

Category :

Cancer

No. of Pages : 302 Pages


Global Markets Directs, Metastatic Colorectal Cancer - Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Colorectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer. Metastatic Colorectal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Colorectal Cancer.
  • A review of the Metastatic Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Colorectal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7

Introduction 8
Global Markets Direct Report Coverage 8
Metastatic Colorectal Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Metastatic Colorectal Cancer 10
Metastatic Colorectal Cancer Therapeutics under Development by Companies 12
Metastatic Colorectal Cancer Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Metastatic Colorectal Cancer Therapeutics Products under Development by Companies 21
Metastatic Colorectal Cancer Therapeutics Products under Investigation by Universities/Institutes 25
Companies Involved in Metastatic Colorectal Cancer Therapeutics Development 26
Bristol-Myers Squibb Company 26
Boehringer Ingelheim GmbH 27
F. Hoffmann-La Roche Ltd. 28
Amgen Inc. 29
AstraZeneca PLC 30
Eli Lilly and Company 31
Genentech, Inc. 32
Nektar Therapeutics 33
Bavarian Nordic A/S 34
Merck & Co., Inc. 35
Light Sciences Oncology, Inc. 36
Celltrion, Inc. 37
Novartis AG 38
Nippon Kayaku Co., Ltd. 39
Pfizer Inc. 40
Taiho Pharmaceutical Co., Ltd. 41
Cell Therapeutics, Inc. 42
Bayer AG 43
Merck KGaA 44
Alchemia Limited 45
IMMUNOMEDICS, INC 46
Oncolytics Biotech Inc. 47
Oncothyreon Inc 48
Zenotech Laboratories Limited 49
Regeneron Pharmaceuticals, Inc. 50
Synta Pharmaceuticals Corp. 51
Morphotek, Inc. 52
Actinium Pharmaceuticals, Inc. 53
Glycotope GmbH 54
OncoMed Pharmaceuticals, Inc. 55
TetraLogic Pharmaceuticals 56
Merrimack Pharmaceuticals, Inc. 57
Jennerex Biotherapeutics, Inc. 58
Syndax Pharmaceuticals, Inc. 59
Globeimmune, Inc. 60
Biothera 61
Cytavis Biopharma GmbH 62
Medical Enzymes AG 63
Therapure Biopharma Inc. 64
Oncozyme Pharma Inc. 65
Metastatic Colorectal Cancer Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 73
trebananib - Drug Profile 73
entinostat - Drug Profile 76
parsatuzumab - Drug Profile 80
regorafenib - Drug Profile 82
DI-17-E-6 - Drug Profile 84
sorafenib tosylate - Drug Profile 86
axitinib - Drug Profile 90
cixutumumab - Drug Profile 93
drozitumab - Drug Profile 96
cediranib maleate - Drug Profile 98
brostallicin - Drug Profile 101
onartuzumab - Drug Profile 103
vismodegib - Drug Profile 105
selumetinib sulfate - Drug Profile 108
irinotecan hydrochloride - Drug Profile 111
pegdinetanib - Drug Profile 113
ganitumab - Drug Profile 115
Afinitor - Drug Profile 118
ramucirumab - Drug Profile 121
ramucirumab - Drug Profile 125
ganetespib - Drug Profile 129
pelareorep - Drug Profile 133
PX-866 - Drug Profile 137
irinotecan hydrochloride nanoliposomal - Drug Profile 140
MORAb-004 - Drug Profile 142
orantinib - Drug Profile 144
(tipiracil hydrochloride + trifluridine) - Drug Profile 146
(tipiracil hydrochloride + trifluridine) - Drug Profile 148
GM-CT-01 - Drug Profile 150
nintedanib - Drug Profile 153
GlutaDON - Drug Profile 155
talaporfin sodium - Drug Profile 157
pentamidine isethionate - Drug Profile 160
TF-2 - Drug Profile 162
aviscumine - Drug Profile 164
demcizumab - Drug Profile 165
GI-4000 - Drug Profile 168
NK-012 - Drug Profile 170
afatinib - Drug Profile 172
dalotuzumab - Drug Profile 174
imgatuzumab - Drug Profile 176
AUY-922 - Drug Profile 178
RG-7597 - Drug Profile 180
yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A + [bevacizumab] + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 182
birinapant - Drug Profile 183
aflibercept - Drug Profile 185
cetuximab biosimilar - Drug Profile 189
IMMU-130 - Drug Profile 190
(tegafur + gimeracil + oteracil potassium) - Drug Profile 191
IMM-101 - Drug Profile 194
FOLF(HA)Iri - Drug Profile 196
TBI-302 - Drug Profile 198
PGG beta-glucan - Drug Profile 199
Dendritic Cell Vaccine - Drug Profile 203
Actimab-C - Drug Profile 204
CV-301 - Drug Profile 205
celecoxib + [capecitabine] - Drug Profile 206
cetuximab Biosimilar - Drug Profile 207
bevacizumab Biosimilar - Drug Profile 208
Metastatic Colorectal Cancer Therapeutics Drug Profile Updates 209
Metastatic Colorectal Cancer Therapeutics Discontinued Products 283
Metastatic Colorectal Cancer Therapeutics - Dormant Products 284
Metastatic Colorectal Cancer Product Development Milestones 287
Featured News & Press Releases 287

Appendix 297
Methodology 297
Coverage 297
Secondary Research 297
Primary Research 297
Expert Panel Validation 297
Contact Us 298
Disclaimer 298

List of Table


Number of Products Under Development for Metastatic Colorectal Cancer, H2 2013 14
Products under Development for Metastatic Colorectal Cancer Comparative Analysis, H2 2013 15
Number of Products under Development by Companies, H2 2013 17
Number of Products under Development by Companies, H2 2013 (Contd..1) 18
Number of Products under Development by Companies, H2 2013 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2013 20
Comparative Analysis by Late Stage Development, H2 2013 21
Comparative Analysis by Mid Clinical Stage Development, H2 2013 22
Comparative Analysis by Early Clinical Stage Development, H2 2013 23
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 24
Products under Development by Companies, H2 2013 25
Products under Development by Companies, H2 2013 (Contd..1) 26
Products under Development by Companies, H2 2013 (Contd..2) 27
Products under Development by Companies, H2 2013 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2013 29
Bristol-Myers Squibb Company, H2 2013 30
Boehringer Ingelheim GmbH, H2 2013 31
F. Hoffmann-La Roche Ltd., H2 2013 32
Amgen Inc., H2 2013 33
AstraZeneca PLC, H2 2013 34
Eli Lilly and Company, H2 2013 35
Genentech, Inc., H2 2013 36
Bavarian Nordic A/S, H2 2013 38
Merck & Co., Inc., H2 2013 39
Light Sciences Oncology, Inc., H2 2013 40
Celltrion, Inc., H2 2013 41
Novartis AG, H2 2013 42
Nippon Kayaku Co., Ltd., H2 2013 43
Pfizer Inc., H2 2013 44
Taiho Pharmaceutical Co., Ltd., H2 2013 45
Cell Therapeutics, Inc., H2 2013 46
Bayer AG, H2 2013 47
Merck KGaA, H2 2013 48
Alchemia Limited, H2 2013 49
IMMUNOMEDICS, INC, H2 2013 50
Oncolytics Biotech Inc., H2 2013 51
Oncothyreon Inc, H2 2013 52
Zenotech Laboratories Limited, H2 2013 53
Regeneron Pharmaceuticals, Inc., H2 2013 54
Synta Pharmaceuticals Corp., H2 2013 55
Morphotek, Inc., H2 2013 56
Actinium Pharmaceuticals, Inc., H2 2013 57
OncoMed Pharmaceuticals, Inc., H2 2013 59
TetraLogic Pharmaceuticals, H2 2013 60
Merrimack Pharmaceuticals, Inc., H2 2013 61
Syndax Pharmaceuticals, Inc., H2 2013 63
Globeimmune, Inc., H2 2013 64
Biothera, H2 2013 65
Cytavis Biopharma GmbH, H2 2013 66
Medical Enzymes AG, H2 2013 67
Therapure Biopharma Inc., H2 2013 68
Oncozyme Pharma Inc., H2 2013 69
Assessment by Monotherapy Products, H2 2013 70
Assessment by Combination Products, H2 2013 71
Assessment by Stage and Route of Administration, H2 2013 73
Assessment by Stage and Molecule Type, H2 2013 76
Metastatic Colorectal Cancer Therapeutics Drug Profile Updates 213
Metastatic Colorectal Cancer Therapeutics Discontinued Products 287
Metastatic Colorectal Cancer Therapeutics Dormant Products 288
Metastatic Colorectal Cancer Therapeutics Dormant Products (Contd..1) 289
Metastatic Colorectal Cancer Therapeutics Dormant Products (Contd..2) 290

List of Chart


Number of Products under Development for Metastatic Colorectal Cancer, H2 2013 14
Products under Development for Metastatic Colorectal Cancer Comparative Analysis, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 20
Late Stage Products, H2 2013 21
Mid Clinical Stage Products, H2 2013 22
Early Clinical Stage Products, H2 2013 23
Pre-Clinical Stage Products, H2 2013 24
Assessment by Monotherapy Products, H2 2013 70
Assessment by Combination Products, H2 2013 71
Assessment by Route of Administration, H2 2013 72
Assessment by Stage and Route of Administration, H2 2013 73
Assessment by Molecule Type, H2 2013 74
Assessment by Stage and Molecule Type, H2 2013 75

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *